This recent transaction increases Allan Rubenstein’s holding in the company by 348% to a total of $1.18 million. This is Rubenstein’s first Buy trade following 35 Sell transactions.
Based on Cooper Co’s latest earnings report for the quarter ending October 31, the company posted quarterly revenue of $652 million and quarterly net profit of $101 million. In comparison, last year the company earned revenue of $562 million and had a net profit of $88.6 million. COO’s market cap is $12.51B and the company has a P/E ratio of 91.93. Currently, Cooper Co has an average volume of 328.3K.
Based on 8 analyst ratings, the analyst consensus is Strong Buy with an average price target of $294.00, reflecting a 15.4% upside. Seven different firms, including Raymond James and BMO Capital, currently also have a Buy rating on the stock. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy COO with a $300 price target.
The insider sentiment on Cooper Co has been negative according to 49 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
The Cooper Cos, Inc. operates as a medical device company. It operates through the following business units: Cooper Vision and Cooper Surgical. The Cooper Vision business unit brings a refreshing perspective on vision care with a commitment to crafting quality lenses for contact lens wearers.